A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...

Piramal Pharma invests $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Vetter Pharma, has begun the construction of a new clinical manufacturing facility in Des Plaines, Illinois, US.

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...